bms-986253
Showing 1 - 5 of 5
MDS Trial run by the National Cancer Institute (NCI) (decitabine and cedazuridine, BMS-986253)
Not yet recruiting
- Myelodysplastic Syndromes
- decitabine and cedazuridine
- BMS-986253
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
NSCLC, Hepatocellular Carcinoma Trial in New York (Nivolumab, BMS-813160, BMS-986253)
Recruiting
- Non-small Cell Lung Cancer
- Hepatocellular Carcinoma
- Nivolumab
- +2 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Oct 14, 2021
Solid Tumor, Sars-CoV2, Hematological Malignancy Trial in New York (BMS-986253)
Terminated
- Solid Tumor
- +2 more
- BMS-986253
-
New York, New YorkColumbia University Irving Medical Center
Nov 18, 2021
Cancer, Melanoma Trial in Worldwide (drug, biological, other)
Recruiting
- Cancer
- Melanoma
- BMS-986253
- +3 more
-
Springdale, Arkansas
- +70 more
May 16, 2022